The inventors – Prof. Robert Langer, Prof. Klavs Jensen and Dr. Armon Sharei – recognized these challenges and sought to develop a more effective delivery technology.
THE SOLUTION: CELLSQUEEZE
The exploratory work led to the development of the CellSqueeze platform. This technology has demonstrated enabling potential in applications ranging from cell therapy to fundamental studies of disease mechanisms.
HOW IT WORKS
In this process, cells are suspended in the desired buffer and are flown through a CellSqueeze chip. The chip contains microfluidic channels that rapidly deform the target cells to induce temporary disruption of the membrane. The delivery material can then enter the cell through the membrane disruptions before they reseal. Our current designs operate at throughputs of over 1,000,000 cells/s and delivery materials are selected to impart a variety of functions on the target cells. This technology thus provides a robust platform for engineering a diversity of cell functions for therapeutic applications.
Through internal research programs and external partnerships, SQZ Biotech is leading a revolution in scientists’ approach to disease research and clinical therapies, developing novel methods to engineer cell function and harnessing the power of a patient’s own cells to combat disease more effectively across a broad range of indications.